CoChat

Laminin, gamma 2 (LAMC2): A Promising New Putative Pancreatic Cancer Biomarker Identified by Proteomic Analysis of Pancreatic Adenocarcinoma Tissues

Open access
Kosanam, Hari, Prassas, Ioannis, Chrystoja, Caitlin C., Soleas, Ireena, Chan, Alison, Dimitromanolakis, Apostolos, Blasutig, Ivan M., Rückert, Felix, Gruetzmann, Robert, Pilarsky, Christian, Maekawa, Masato, Brand, Randall, Diamandis, Eleftherios P. · 2013 · Molecular & Cellular Proteomics
Cited by 118

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

In pancreatic cancer, the incidence and mortality curves coincide. One major reason for this high mortality rate in pancreatic ductal adenocarcinoma (PDAC) patients is the dearth of effective diagnostic, prognostic, and disease-monitoring biomarkers. Unfortunately, existing tumor markers, as well as current imaging modalities, are not sufficiently sensitive and/or specific for early-stage diagnosis. There is, therefore, an urgent need for improved serum markers of the disease. Herein, we performed Orbitrap® mass spectrometry proteomic analysis of four PDAC tissues and their adjacent benign tissues and identified a total of 2190 nonredundant proteins. Sixteen promising candidates were selected for further scrutiny using a systematic scoring algorithm. Our preliminary serum verification of the top four candidates (DSP, LAMC2, GP73, and DSG2) in 20 patients diagnosed with pancreatic cancer and 20 with benign pancreatic cysts, showed a significant (p < 0.05) elevation of LAMC2 in pancreatic cancer serum. Extensive validation of LAMC2 in healthy, benign, and PDAC sera from geographically diverse cohorts (n = 425) (Japan, Europe, and USA) demonstrated a significant increase in levels in early-stage PDAC compared with benign diseases. The sensitivity of LAMC2 was comparable to CA19.9 in all data sets, with an AUC value greater than 0.85 in discriminating healthy patients from early-stage PDAC patients. LAMC2 exhibited diagnostic complementarity with CA19.9 by showing significant (p < 0.001 in two out of three cohorts) elevation in PDAC patients with clinically low CA19.9 levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/mcp.m112.023507

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. Singh, 2011, Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment, Pancreas, 40, 644, 10.1097/MPA.0b013e31821ff741 · DOI
  2. Spratlin, 2011, Looking to the future: biomarkers in the management of pancreatic adenocarcinoma, Int. J. Mol. Sci., 12, 5895, 10.3390/ijms12095895 · DOI
  3. Goonetilleke, 2007, Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer, Eur. J. Surg. Oncol., 33, 266, 10.1016/j.ejso.2006.10.004 · DOI · Paper page
  4. Singh, 2011, The clinical utility and limitations of serum carbohydrate antigen (CA19–9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma, Dig. Dis. Sci., 56, 2491, 10.1007/s10620-011-1709-8 · DOI
  5. Makawita, 2011, Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers, Mol. Cell. Proteomics, 10, 10.1074/mcp.M111.008599 · DOI · Paper page
  6. Kosanam, 2011, Mining the malignant ascites proteome for pancreatic cancer biomarkers, Proteomics, 11, 4551, 10.1002/pmic.201100264 · doi:10.1002/pmic.201100264
  7. DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 · DOI · Paper page
  8. Lianidou, 2011, Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges, Clin. Chem., 57, 1242, 10.1373/clinchem.2011.165068 · DOI · Paper page
  9. Haglund, 1986, Evaluation of CA 19–9 as a serum tumour marker in pancreatic cancer, Br. J. Cancer, 53, 197, 10.1038/bjc.1986.35 · DOI
  10. Perkins, 2003, Serum tumor markers, Am. Fam. Physician, 68, 1075
  11. Lu, 2004, Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue, Proteomics, 4, 3975, 10.1002/pmic.200300863 · DOI
  12. Cui, 2009, Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma, Pancreatology, 9, 89, 10.1159/000178879 · doi:10.1159/000178879
  13. Turtoi, 2011, Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma, J. Proteome Res., 10, 4302, 10.1021/pr200527z · DOI
  14. Kulasingam, 2010, Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer, Nat. Rev. Cancer, 10, 371, 10.1038/nrc2831 · DOI
  15. Planque, 2009, Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines, Mol. Cell. Proteomics, 8, 2746, 10.1074/mcp.M900134-MCP200 · DOI · Paper page
  16. Badea, 2008, Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia, Hepatogastroenterology, 55, 2016
  17. Mitsunaga, 2010, Nerve invasion distance is dependent on laminin gamma2 in tumors of pancreatic cancer, Int. J. Cancer, 127, 805, 10.1002/ijc.25104 · doi:10.1002/ijc.25104
  18. Dusek, 2011, Desmosomes: new perpetrators in tumour suppression, Nat. Rev. Cancer, 11, 317, 10.1038/nrc3051 · DOI · Paper page
  19. Ramani, 2008, Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer, BMC Cancer, 8, 373, 10.1186/1471-2407-8-373 · DOI
  20. Mao, 2010, Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma, Gut, 59, 1687, 10.1136/gut.2010.214916 · DOI · Paper page
  21. Koopmann, 2006, Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19–9, Clin. Cancer Res., 12, 442, 10.1158/1078-0432.CCR-05-0564 · DOI · Paper page
  22. Argani, 2001, Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE), Clin. Cancer Res., 7, 3862
  23. Eskelinen, 1999, Developments in serologic detection of human pancreatic adenocarcinoma, Scand. J. Gastroenterol., 34, 833, 10.1080/003655299750025273 · doi:10.1080/003655299750025273
  24. Hustinx, 2004, Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression, Cancer Biol. Ther., 3, 1254, 10.4161/cbt.3.12.1238 · DOI
  25. Slesak, 2000, Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19–9, Cancer, 89, 83, 10.1002/1097-0142(20000701)89:1<83::AID-CNCR12>3.0.CO;2-J · doi:10.1002/1097-0142(20000701)89:1<83::aid-cncr12>3.0.co;2-j
  26. Zhou, 1998, Identifying markers for pancreatic cancer by gene expression analysis, Cancer Epidemiol. Biomarkers Prev., 7, 109
  27. Moniaux, 2008, Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia, Br. J. Cancer, 98, 1540, 10.1038/sj.bjc.6604329 · DOI · Paper page
  28. Faca, 2008, A mouse to human search for plasma proteome changes associated with pancreatic tumor development, PLoS Med., 5, 953, 10.1371/journal.pmed.0050123 · DOI · Paper page
  29. Bansal, 1995, Pancreatitis is a risk factor for pancreatic cancer, Gastroenterology, 109, 247, 10.1016/0016-5085(95)90291-0 · DOI · Paper page
  30. Costello, 2012, New biomarkers and targets in pancreatic cancer and their application to treatment, Nature Revi., 9, 435
  31. Haeno, 2012, Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies, Cell, 148, 365, 10.1016/j.cell.2011.11.060 · DOI · Paper page

Cited by

See all 118

Metadata

Authors
Kosanam, H., Prassas, I., Chrystoja, C. C., Soleas, I., Chan, A., Dimitromanolakis, A., Blasutig, I. M., Rückert, F., Gruetzmann, R., Pilarsky, C., Maekawa, M., Brand, R., & Diamandis, E. P.
Venue
Molecular & Cellular Proteomics
Publisher
Elsevier BV
Published
2013-10
Volume
12
Issue
10
Pages
2820-2832
ISSN
1535-9476 (ISSN-L)
OpenAlex
W2117331236
Cited by
118
References
3
FWCI
4.58
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.